Kusuri Context Studio
Back to articles

Why was Rozerem S approved only for difficulty falling asleep?

Trouble falling asleep and waking repeatedly during the night are both sleep problems. When reading a medicine's approved indication, that distinction matters.

Rozerem S, a ramelteon product sold in Japan under pharmacist guidance, is approved for temporary difficulty falling asleep. The original application also included light sleep. During the review, the applicant was asked to align the proposed indication with that of prescription Rozerem and narrowed it to difficulty falling asleep.

What, then, did the trials measure about sleep after people had fallen asleep?

Ministry committee minutes (Japanese) · Product information (Japanese)

Continue on note

The full article looks at what the trials measured and how the findings relate to the approved indication. It is available as a paid article in Japanese on note.

Read the article on note